推荐产品
生物来源
mouse
质量水平
100
500
偶联物
unconjugated
抗体形式
culture supernatant
抗体产品类型
primary antibodies
克隆
MRQ-36, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形式
buffered aqueous solution
种属反应性
human
包装
vial of 0.1 mL concentrate (119M-14)
vial of 0.5 mL concentrate (119M-15)
bottle of 1.0 mL predilute (119M-17)
vial of 1.0 mL concentrate (119M-16)
bottle of 7.0 mL predilute (119M-18)
制造商/商品名称
Cell Marque™
技术
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
同位素/亚型
IgG1κ
控制
tonsil
运输
wet ice
储存温度
2-8°C
可视化
membranous
基因信息
human ... CD19(930)
一般描述
CD19 is present in both normal and malignant B-cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, mantle zone cells, and scattered cells in the interfollicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in immature B-cells; although recent studies have described CD19 loss in a few B-cell neoplasms.
质量
 IVD |  IVD |  IVD |  RUO |
联系
CD19 Positive Control Slides, Product No. 119S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外形
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
制备说明
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他说明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律信息
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
法规信息
监管及禁止进口产品
S A Greenberg et al.
Neurology, 65(11), 1782-1787 (2005-12-14)
Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral mechanisms. Microarray studies were performed on muscle biopsy
Y K Onno Teng et al.
Arthritis and rheumatism, 56(12), 3909-3918 (2007-12-01)
Anti-CD20-mediated B cell depletion with rituximab is a new and effective therapy for rheumatoid arthritis (RA). Although B cells in peripheral blood (PB) are consistently depleted in all patients, the clinical effects are more heterogeneous, possibly related to differences in
Miho Kimura et al.
International journal of hematology, 85(1), 41-48 (2007-01-31)
To clarify the clinicopathologic significance of a loss of CD19 expression in diffuse large B-cell lymphoma (DLBCL), we evaluated CD19 expression immunohistochemically in frozen sections from 227 patients who had received diagnoses of DLBCL according to the World Health Organization
Oliver M Steinmetz et al.
Transplantation, 84(7), 842-850 (2007-11-07)
Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently
N Masir et al.
Histopathology, 48(3), 239-246 (2006-01-25)
To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. A polyclonal antibody to the C terminus of CD19 was used to immunostain
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门